Has Priscilla Cooney received payments from drug or device companies?

Yes. Drug and device makers reported $10,525 in general payments to Priscilla Cooney across 570 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Priscilla Cooney did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Priscilla Cooney come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Priscilla Cooney

Family · Kingston, PANPI 1649401902

Payments from drug & device makers

$10,525in general payments, 2019–2025

Across 570 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$908
Novartis$792
Pfizer$745
AstraZeneca$726
Genentech USA, Inc.$503
E.r. Squibb & Sons, L.L.C.$452
plus $6K from 54 others

What the payments were for

Food & beverage$10,39899%
Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	66	$908
Novartis	44	$792
Pfizer	48	$745
AstraZeneca(2 entities)	35	$726
Genentech USA, Inc.	23	$503
E.r. Squibb & Sons, L.L.C.	27	$452
Bristol Myers Squibb	31	$418
Celltrion USA Inc.	3	$397
Merck	23	$352
Johnson & Johnson	14	$295
Sanofi	15	$279
AbbVie	10	$234
Gilead(2 entities)	13	$229
GSK	10	$226
Amgen	12	$213
Incyte Corporation	11	$203
Eisai Inc.	10	$198
Seagen Inc.	9	$187
Astellas Pharma US Inc	10	$176
Lilly USA, LLC	10	$174
Takeda Pharmaceuticals U.S.A., Inc.	9	$166
Array Biopharma Inc	12	$165
Pharmacosmos Therapeutics Inc.	7	$153
Beigene USA, Inc.	7	$151
Sobi, Inc	7	$143
Jazz Pharmaceuticals Inc.	6	$128
Exelixis Inc.	6	$126
EMD Serono, Inc.	6	$119
Rigel Pharmaceuticals, Inc.	7	$116
Mirati Therapeutics, Inc.	5	$95
Taiho Oncology, Inc.	5	$95
Stemline Therapeutics Inc.	4	$85
Genmab U.S., Inc.	3	$75
Coherus Oncology, Inc.	5	$74
Pharmacyclics LLC, An Abbvie Company	4	$74
Regeneron Healthcare Solutions, Inc.	3	$72
Boehringer Ingelheim	4	$64
Organon	3	$61
Karyopharm Therapeutics Inc.	3	$56
Geron Corporation	2	$56
Beone Medicines USA, Inc.	2	$52
Ipsen Biopharmaceuticals, Inc	3	$51
Blueprint Medicines Corporation	1	$50
Shield Therapeutics Inc	3	$47
Puma Biotechnology, Inc.	2	$45
Pharmaessentia USA Corporation	2	$42
Servier Pharmaceuticals LLC	2	$42
Kyowa Kirin, Inc.	2	$41
Tersera Therapeutics LLC	2	$39
AVEO Pharmaceuticals, Inc.	2	$36
Apellis Pharmaceuticals, Inc.	2	$34
Sumitomo Pharma America, Inc.	2	$33
Immunogen, Inc.	2	$31
Foundation Medicine, Inc.	1	$31
Bayer	1	$28
G1 Therapeutics, Inc.	1	$25
Sanofi-aventis U.S. LLC	1	$20
Deciphera Pharmaceuticals Inc.	1	$15
Dova Pharmaceuticals	1	$15
CTI Biopharma Corp.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VEGZELMA$340

How this compares

$10,525 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	40	$23,315
XareltoRivaroxaban	11	$6,630
Exemestane	70	$5,751
Letrozole	66	$1,675
Hydroxyurea	56	$1,297
Prochlorperazine Maleate	79	$813
Tamoxifen Citrate	21	$440
Potassium Chloride	69	$398
Escitalopram Oxalate	17	$381
Alendronate Sodium	36	$355
Oxycodone Hcl	40	$336
Levothyroxine Sodium	77	$304
Minocycline Hcl	17	$290
Acyclovir	31	$272
Dexamethasone	36	$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$745	$23,31540 claims
Johnson & JohnsonXarelto	$295	$6,63011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Kingston

Kathleen ScholzPittsburgh$397K
Shannon FitzgeraldAllison Park$370K
Stephanie HarshbargerCamp Hill$317K
Whitney BowlesFort Washington$253K
Kweilynn GreenePittsburgh$139K
Jessica LindenbergerPittsburgh$131K
Kami NestlerWilkes Barre$129K
Bethany ThomasPhiladelphia$126K
Margaret RosenzweigPittsburgh$89K
Amanda GrippoDickson Cty$86K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →